Dexcom (DXCM) Revenue (2010 - 2026)

Dexcom (DXCM) has 17 years of Revenue data on file, last reported at $1.2 billion in Q1 2026.

• On a quarterly basis, Revenue rose 15.05% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $4.8 billion, a 16.15% increase from a year earlier, with the FY2025 full-year figure at $4.7 billion, up 15.6% from the prior year.
• Revenue for Q1 2026 stood at $1.2 billion, down from $1.3 billion in the prior quarter.
• Over the last five years, Revenue for DXCM reached as high as $1.3 billion in Q4 2025 and fell as low as $628.8 million in Q1 2022.
• Historically, Revenue has averaged $965.8 million across 5 years, with a median of $994.2 million in 2024.
• Across the five-year window, Revenue rose 26.9% in 2023 and climbed 1.97% in 2024, its largest moves.
• Year by year, Revenue stood at $815.2 million in 2022, then advanced by 26.9% to $1.0 billion in 2023, then rose by 7.64% to $1.1 billion in 2024, then climbed by 13.12% to $1.3 billion in 2025, then retreated by 5.37% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Revenue figures were $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.